Utility of PET/CT in diagnosis, staging, assessment of resectability and metabolic response of pancreatic cancer

Table 3 ¹⁸F-fluorodeoxyglucose-position emission tomography/computed tomography in N-staging and detection of liver metastasis of pancreatic cancer

Ref.	Study design	SE (%) (true positive/total positive)
		PET/CT	CT	P value
N-staging
Heinrich et al[32]	P	21.42 (3/14)	-	-
Maemura et al[59]	R	50.00 (3/6)	66.67 (4/6)	0.56
1Wakabayashi et al[51]	P	57.10 (8/14)	78.6 (11/14)	0.42
Kauhanen et al[29]	P	38	-	-
1Imai et al[60]	R	0 (0/6)	0 (0/6)
Detection of liver metastasis
Fröhlich et al[63]	R	68 (15/22)
Mertz et al[21]	R	78 (7/9)	33.33 (3/9)	0.06
Lytras et al[18]	R	22	20	0.81
Heinrich et al[32]	P	81 (13/16)	56 (9/16)	0.22
Maemura et al[59]	R	37.5 (3/8)	87.5 (7/8)	0.04
Wakabayashi et al[51]	P	52.6 (10/19)	73.7 (14/19)	0.18
Farma et al[62]	R	61	57
Strobel et al[52]	R	46 (5/11)
Kauhanen et al[29]	P	88(6/7)	42.86 (3/7)	0.09

¹¹⁸F-fluorodeoxyglucose-position emission tomography (FDG-PET) scan without computed tomography (CT). SE: Sensitivity; SP: Specificity; NPV: Negative predictive value; PPV: Positive predictive value; R: Retrospective study; P: Prospective study.